✦ LIBER ✦

22 Costs of cisplatin and carboplatin in combination with gemcitabine in advanced non-small cell lung cancer: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients

✍ Scribed by Gaunt, P.; Frew, E.; Jarrett, H.; Billingham, L.; Ferry, D.; Dunlop, D.; Thompson, J.; O'Byrne, K.

Book ID: 118574963
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 44 KB
Volume: 75
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(12)70023-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O-90 Randomised phase III trial of docet

O-90 Randomised phase III trial of docetaxel/carboplatin vs. MIC/MVP chemotherapy in inoperable advanced non-small cell lung cancer (NSCLC) — A British thoracic oncology group (BTOG) trial

✍ Booton, Richard; Ascroft, Linda; Stout, Ron; Lorigan, Paul; Faivre-Finn, Corinne 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Gefitinib in Combination With Gemcitabin

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial--INTACT 1

✍ Giaccone, G. 📂 Article 📅 2004 🏛 American Society of Clinical Oncology 🌐 English ⚖ 430 KB

O-095 A phase III trial of docetaxel/car

O-095 A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small cell lung cancer — A randomised multicentre trial of the British thoracic oncology group (BTOG1)

✍ Lorigan, P. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Phase III Study of Erlotinib in Combinat

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

✍ Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 169 KB

Phase III Study of Erlotinib in Combinat

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

✍ Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 169 KB

## Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase, with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of chemotherapy. This phase III, randomized, double-blind, placebo-controlled, multicenter trial evaluated th

Randomized phase III trial of Taxol®/Car

Randomized phase III trial of Taxol®/Carboplatin versus Taxol®Cisplatin in patients with advanced non-small cell lung cancer

✍ Rosell, R.; Gatzemeier, U.; Betticher, D.; Keppler, U.; Macha, H.N.; Pirker, R.; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 98 KB